Centessa ‘Creates Pharma Pipeline Overnight’ Using Novel R&D Approach
Centessa CEO Saurabh Saha Outlines Strategy For New Company Built From A Merger Of 10 Biotechs
With $250m in series A funding, Cambridge, MA-based Centessa is looking to upend traditional biopharma R&D models. The new company was created through the merger of 10 private biotechs, which will sit under the Centessa umbrella as subsidiaries.
You may also be interested in...
Following early investor conversations, Laevoroc Oncology has split its leading products into three independent subsidiaries to off-set risk and provide greater choice to future partners. While there is no underlying platform technology, CEO Thomas Mehrling believes the subsidiaries all include potential “game-changing medicines.”
A selection of articles you might have missed from July 2021, including exclusive interviews with industry leaders and a deep dive into the RNA therapy pipeline.
With digital therapies and devices seeing widespread adoption in response to lockdown limitations during the COVID-19 pandemic, Kaiku Health is in a strong position to expand its patient monitoring software. CEO Lauri Sippola spoke with In Vivo about the platform and the company’s plans for 2021 and beyond.